ARTL Stock Overview
A clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Artelo Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$1.75 |
| 52 Week Low | US$1.00 |
| Beta | 1.35 |
| 11 Month Change | -7.88% |
| 3 Month Change | -13.28% |
| 1 Year Change | -13.28% |
| 33 Year Change | -89.59% |
| 5 Year Change | -96.96% |
| Change since IPO | -98.15% |
Recent News & Updates
Recent updates
Artelo jumps 21% as publication highlights pre-clinical data on drug platform
Aug 16Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans
Mar 28
Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy
Mar 09Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?
Nov 02Relief For Cancer Patients In Artelo Bioscience Pipeline
Jul 12Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans
May 20Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?
Feb 04INO, VXRT, BTU and TTM among premarket gainers
Feb 02Artelo Biosciences EPS misses by $0.04
Jan 14Artelo Biosciences on go with cancer appetite recovery study
Nov 16Shareholder Returns
| ARTL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.7% | -1.4% | 0.3% |
| 1Y | -13.3% | 10.8% | 31.1% |
Return vs Industry: ARTL underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: ARTL underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| ARTL volatility | |
|---|---|
| ARTL Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARTL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ARTL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 5 | Greg Gorgas | www.artelobio.com |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017.
Artelo Biosciences, Inc. Fundamentals Summary
| ARTL fundamental statistics | |
|---|---|
| Market cap | US$3.65m |
| Earnings (TTM) | -US$9.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs ARTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARTL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.12m |
| Earnings | -US$9.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.83 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ARTL perform over the long term?
See historical performance and comparison